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Background
The best treatment for patients with pathological stage I–
II malignant melanoma (sec AJCC) remains controversial
because patients are unlikely to benefit from routine lym-
phoadenectomy (over treatment risk 80%) in this stage.
On the other hand, pitfalls in the identification of occult
melanoma are significant (20%). Our objective was to
evaluate the single center application of sentinel lym-
phoadenectomy for the management of early stage
melanoma. The sentinel lymph node biopsy (SLN) is a
minimally invasive technique of staging the regional
lymph nodes for melanoma that balance risks and effec-
tiveness.
Methods
From April 2002 a total of 124 patients with mean age of
56.9 (range 21–90) years, were studied in the multidisci-
plinary outpatient clinic for melanoma at "Ospedale di
Valdagno – ULSS 5". We analyzed 83 patients treated
from 2002 through 2008 who underwent SLN biopsy for
melanoma. Candidates for SLN are patients with thick pri-
mary melanoma (>1 mm sec Breslow) or less if ulcerated
or with regression. One day before surgery, lymphoscin-
tigraphy has been performed using 99 mTc-human serum
albumin. Intraoperatively, blue dye was injected around
the primary site and the nodes were identified using both
blue dye and hand-held gamma probe.
Results
Of the 124 patients, 44 were over 65 years old (35.4%); 27
male and 17 female with mean age of 75.3 years (66–90).
Primaries were on head/neck (n = 18), trunk (n = 11),
upper extremities (n = 7), lower extremities (n = 8). The
most common histology was superficial spreading (18)
followed by: 11 nodular melanoma, 12 melanoma on
lentigo maligna, 1 acral melanoma, 2 metastases of
unknown origin. The median tumour thickness was 3.56
mm (0.5–10) and 7 were melanoma ulcerated; 5
melanoma with regression. Among these patients we per-
formed 17 SLN. Metastases in sentinel node were present
in 2 cases (11.6%). A man with ulcerated melanoma of
the trunk with tumor thickness >5 mm underwent axillar-
ies lymphoadenectomy (25 lymph node removed, 0
metastases) and an 88 year-old female with in-transit
metastases (primary knee melanoma) underwent
inguinal-crural-otturatory lymphadenectomy (27 nodes
removed, 0 metastases). Median hospital stay for the last
2 patients was 5 days and the post-operative course was
uneventful.
Conclusion
SLN status is the most important prognostic factor in stage
I–II malignant melanoma. Indeed, after 27 months fol-
low-up in 612 SLN-negative patients, disease-free survival
was 91%, recurrence rate was 9% and mortality rate was
less than 2%. In the SLN-positive group overall survival
was 77% and recurrence rate of 33% with a mortality rate
of 16%. The procedure helps to identify high-risk recur-
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rence patients, and stratify these patients into more
aggressive adjuvant therapy. SLN is widely accepted even
in older population however in those patients relation-
ship between age and SLNB is not established.Page 2 of 2
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